California nursing exec gets six years in prison for Medicare fraud

Share this article:

The former chief of a California nursing home has been handed a six-and-a-half year prison sentence for his role in fraudulently inflating Medicare reimbursement payments by about $3 million through the late 1990s and beyond.

St. Luke's Subacute Hospital and Nursing Centre in San Leandro, CA, also was placed on five years probation for the crimes, according to the U.S. Attorney for the Northern District of California.

A federal grand jury indicted CEO Guy Roland Seaton and the facility, which is also known as Seaton Rehabilitation Hospital, in May 2001 on charges including conspiracy, false claims counts, submitting false statements, obstruction of federal auditing, and aiding and abetting. The indictment capped a nine-year investigation by multiple federal agencies. Convictions followed in December 2002.

Prosecutors said Seaton used his 72-bed facility to file fraudulent nursing costs to fiscal intermediary Mutual of Omaha. Authorities said Seaton told employees to falsify nursing schedules for investigators, who wound up uncovering the ploy by comparing those submissions with even earlier records.

Seaton and the facility also must pay restitution, and Seaton will serve three years of supervised release after his prison term.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.